Application of the fibrosis-4 score in a generalised population

Table 1 Range of values from initial validation population of the fibrosis-4 score, range

	Range in initial validation set	Reference ranges
ALT (U/L)	14-156	5-40
AST (U/L)	13-97	5-40
Platelets	130-258 × 109/L	150-410 × 109/L
Age (years)	33-47	NA
BMI (kg/m2)	20-28	18.5-24.9
Albumin (U/L)	38-46	35-50

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NA: Not applicable; BMI: Body mass index.

Table 2 Breakdown of patients meeting initial validation criteria, n (%)

Criterion	Number (n = 462)	Number (n = 89)
Age 33-47 (years)	89 (19)
ALT 14-156 (U/L)	288 (62)	82 (92)
AST 13-97 (U/L)	439 (95)	86 (97)
Platelets 130-258	224 (48)	39 (44)
Albumin 38-46 (U/L)	349 (76)	64 (72)
Met all 5 criteria	24 (5)	24 (27)

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.

Table 3 Features of remaining patients

ID	Note on patient	FIB-4 calculated	Radiological evidence of steatosis
I	Had no present nor historical LFT derangement	0.55	No US abdomen performed
II	FIB-4 incalculable on previously deranged LFTs; FIB-4 calculated on normal LFTs	0.72	No US abdomen performed
III	Had no present nor historical LFT derangement	0.87	No US abdomen performed
IV	FIB-4 incalculable on previously deranged LFTs; FIB-4 calculated on deranged LFTs	Fibro scan suggested	Mild heterogenous liver echotexture with no obvious focal pathology identified

FIB-4: Fibrosis-4; LFT: Liver functions tests; US: Ultrasound.